Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 45,755 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 45,755 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $22.97, for a total transaction of $1,050,992.35. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $769,540.94. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, June 4th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.88, for a total transaction of $3,755,093.44.
• On Wednesday, May 1st, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.54, for a total transaction of $2,368,655.52.
• On Thursday, April 4th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.97, for a total transaction of $2,827,653.36.

Hims & Hers Health Price Performance

HIMS opened at $22.29 on Monday. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74. The stock has a market cap of $4.79 billion, a P/E ratio of -2,215.00 and a beta of 1.08. The stock’s 50 day simple moving average is $16.70 and its 200 day simple moving average is $13.10.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. During the same quarter last year, the business posted ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Research analysts expect that Hims & Hers Health, Inc. will post 0.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $48,000. Avantax Advisory Services Inc. acquired a new position in shares of Hims & Hers Health during the 1st quarter worth approximately $156,000. Cornerstone Investment Partners LLC acquired a new position in shares of Hims & Hers Health during the 1st quarter worth approximately $161,000. Belpointe Asset Management LLC acquired a new position in shares of Hims & Hers Health during the 3rd quarter worth approximately $76,000. Finally, Certuity LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $109,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. SVB Leerink assumed coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They issued a “market perform” rating and a $10.00 target price on the stock. Citigroup cut shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $16.00 to $20.00 in a research note on Wednesday, May 22nd. Finally, Guggenheim boosted their price objective on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average target price of $16.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.